Actively Exploring Partnership for Alzheimer’s DevelopmentSupplementary Financing Concluded in Q4ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE ...

Lecanemab, a drug designed to slow the progression of early stage Alzheimer's will not be available to patients in Sweden for ...

Both Alzheimer’s disease (AD) and cerebral small vessel disease (CSVD) manifest in cognitive impairment and gait disorders. The precise similarities and differences in gait characteristics and ...

The researchers tracked how these people moved between various states: healthy, mild cognitive impairment, and dementia. They also considered the possibility of reversals, where individuals improved ...

Early detection allows for prompt intervention that may slow progression and help manage fears, Dr. Harinderjeet Kaur writes.

A woman’s “body clock” might affect her dementia risk, according to a new study. The timing of an older woman’s sleep/wake ...

Can dementia lead to death? Yes, though not directly fatal, dementia severely impacts the body, leading to complications like ...

Blurring memory. Affects that cancel each other out. The mind that appears distant, almost unattainable. As if an ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

A study of 204 low-income older adults found that 3 out of 4 had undiagnosed cognitive issues — including some who didn’t ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

After re-examining its initial opinion, EMA’s human medicines committee, or CHMP, has recommended granting a marketing authorisation to Leqembi for treating mild cognitive impairment or mild dementia ...